ES2175400T3 - Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer. - Google Patents

Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.

Info

Publication number
ES2175400T3
ES2175400T3 ES97920514T ES97920514T ES2175400T3 ES 2175400 T3 ES2175400 T3 ES 2175400T3 ES 97920514 T ES97920514 T ES 97920514T ES 97920514 T ES97920514 T ES 97920514T ES 2175400 T3 ES2175400 T3 ES 2175400T3
Authority
ES
Spain
Prior art keywords
disease
alzheimer
activated
lymphocytes
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97920514T
Other languages
English (en)
Inventor
Manfred Dr Hartwig
Jorg Prof Dr Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHULZ JORG PROF DR MED
Original Assignee
SCHULZ JORG PROF DR MED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19608519A external-priority patent/DE19608519A1/de
Priority claimed from DE1996132671 external-priority patent/DE19632671A1/de
Priority claimed from DE1996140348 external-priority patent/DE19640348A1/de
Application filed by SCHULZ JORG PROF DR MED filed Critical SCHULZ JORG PROF DR MED
Application granted granted Critical
Publication of ES2175400T3 publication Critical patent/ES2175400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA DIAGNOSTICAR LA ENFERMEDAD DE ALZHEIMER Y ENFERMEDADES CON UNA ETIOLOGIA SIMILAR, ASI COMO A MEDIOS FARMACEUTICOS PARA SU TRATAMIENTO. LOS CAMPOS DE APLICACION DE LA INVENCION SON LA MEDICINA Y LA INDUSTRIA FARMACEUTICA. EL PUNTO DE PARTIDA DE LA INVENCION ES EL SORPRENDENTE DESCUBRIMIENTO DE QUE UN FACTOR CAUSANTE DE LA ENFERMEDAD DE ALZHEIMER ES LA PRODUCCION PATOLOGICA DE LINFOCITOS T ACTIVADOS AUTOESPECIFICOS EN LA SANGRE PERIFERICA. LOS LINFOCITOS T ACTIVADOS ATRAVIESAN LA BARRERA HEMATOENCEFALICA, SUCUMBEN FRENTE A LA APOPTOSIS AL ACTUAR JUNTO CON CELULAS DE LA MICROGLIA Y, CON LA ACTIVACION DE LA MICROGLIA, ACTIVAN EL PROCESO DE ENCENDIDO NEUROTOXICO CARACTERISTICO. EL PROCEDIMIENTO CONFORME A LA INVENCION UTILIZA UNA MUESTRA DE SANGRE PERIFERICA, A PARTIR DE LA CUAL SE DIAGNOSTICA LA ENFERMEDAD DE ALZHEIMER CON BASE EN LA PROPORCION DE CELULAS MONONUCLEARES APOPTOSICAS (MURIENTES), EN LA ACTIVACION DE MONOCITOS/MACROFAGOS O EN AMBOS METODOS EN COMBINACION. EL MEDIO CONFORME A LA INVENCION CONTIENE COMO SUSTANCIA ACTIVA UN FACTOR QUE AUMENTA LA ACTIVIDAD FAGOCITICA EN EL CUERPO Y EN UN ORGANO ESPECIFICO, EN ESPECIAL EN EL CEREBRO, O BIEN UNA SUSTANCIA QUE SE FIJA SELECTIVAMENTE A MARCADORES DE ACTIVACION O RECEPTORES DE ADHESION DE LINFOCITOS L ACTIVADOS O A RECEPTORES DE ADHESION DE CELULAS ENDOTELIALES.
ES97920514T 1996-03-06 1997-03-03 Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer. Expired - Lifetime ES2175400T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19608519A DE19608519A1 (de) 1996-03-06 1996-03-06 Mittel zur Therapie der Alzheimer-Krankheit und von Krankheiten analoger Ursache
DE1996132671 DE19632671A1 (de) 1996-08-14 1996-08-14 Verfahren zur Diagnostik der Alzheimer-Krankheit
DE1996140348 DE19640348A1 (de) 1996-09-20 1996-09-20 Mittel zur Therapie der Alzheimer-Krankheit

Publications (1)

Publication Number Publication Date
ES2175400T3 true ES2175400T3 (es) 2002-11-16

Family

ID=27215983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97920514T Expired - Lifetime ES2175400T3 (es) 1996-03-06 1997-03-03 Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.

Country Status (5)

Country Link
EP (1) EP0885392B1 (es)
AT (1) ATE213067T1 (es)
DE (1) DE59706309D1 (es)
ES (1) ES2175400T3 (es)
WO (1) WO1997033175A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
GB0802851D0 (en) 2008-02-15 2008-03-26 Medinnova As Diagnostic method
DE202009018142U1 (de) 2009-05-09 2011-02-24 Kettenbach Gmbh & Co. Kg Härtbare Zusammensetzungen, daraus hergestellte gehärtete Produkte und deren Verwendung
JP2014502356A (ja) * 2010-11-24 2014-01-30 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイン病のマーカーとしての食作用活性

Also Published As

Publication number Publication date
EP0885392B1 (de) 2002-02-06
WO1997033175A1 (de) 1997-09-12
EP0885392A1 (de) 1998-12-23
ATE213067T1 (de) 2002-02-15
DE59706309D1 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
Novak Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report
Yung et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Tedesco et al. Effects of losartan on hypertension and left ventricular mass: a long-term study
ES2185712T3 (es) Procedimientos y equipos de analisis para el diagnostico especifico y sensible de las enfermedades periodontales.
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
DE69632601D1 (de) Auf Kodes für Herzschläge basierendes Gerät für Diagnose und Behandlung von Herzarryhythmie
MXPA05008487A (es) Acidos nucleicos expresados en forma diferencial en la barrera hemato-encefalica bajo condiciones de inflamacion.
EP1706145A4 (en) AUTOANTIC BODY USED IN TUMOR IMAGING AND CANCER TREATMENT AS A CARRIER FOR PHARMACEUTICAL COMPOUNDS
ES2175400T3 (es) Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
EP0752872A4 (en) NADH OXIDASE AS A TARGET IN DIAGNOSTIC AND THERAPEUTIC PROCESSES
Le Melledo et al. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide
BR0318166A (pt) uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
IT1283899B1 (it) Peptidi e loro usi nella terapia della malattia celiaca
Drake Jr et al. Contingent negative variation in epilepsy
RU2150292C1 (ru) Способ лечения ишемической болезни сердца
RU94000526A (ru) Способ диагностики адаптации организма человека зрелого и пожилого возраста
Halgren et al. Post‐EEG Seizure Depression of Human Limbic Neurons Is Not Détérmined by Their Response to Probable Hypoxia
Hulme et al. Skin cleansing as an accompaniment to acne therapy.
Shikanai et al. Diazepam-Induced Increases of Synaptic Efficacy in the Hippocampal–Medial Prefrontal Cortex Pathway Are Associated With Its Anxiolytic-like Effect in Rats
SU1542548A1 (ru) Способ купировани болевого синдрома у больных стенокардией
Nannan et al. The Mechanism and Potential Therapeutic Targets of SUMOylation in Ischemic Stroke
Grotta Distal basilar artery occlusion syndrome
Takebayashi et al. Plasma dehydraepiandrosterone sulfate and cortisol measurements in major depression

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885392

Country of ref document: ES